Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, March 29, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Whistleblower

The Ninth Circuit on Thursday revived part of a man’s whistleblower claims against three pharmaceutical companies that he said promoted dangerous off-label uses of the heart drug Integrilin, so the trial court can determine if the whistleblower is an “original source” of the information.

SAN FRANCISCO – The Ninth Circuit on Thursday revived part of a man’s whistleblower claims against three pharmaceutical companies that he said promoted dangerous off-label uses of the heart drug Integrilin, so the trial court can determine if the whistleblower is an “original source” of the information.

Categories / Appeals, Business, Consumers

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...